Novel vaccine vectors for HIV.1

Nature Reviews Microbiology

Volumn 12, Issue 11, 2014, Pages 765-771

  Barouch, Dan H ^a,b   Picker, Louis J ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOMEGALOVIRUS VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADENOVIRIDAE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SEROTYPE; SIMIAN IMMUNODEFICIENCY VIRUS; ANIMAL; DISEASE MODEL; GENE VECTOR; HIV INFECTIONS; IMMUNOLOGY;

ADENOVIRIDAE; CYTOMEGALOVIRUS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84922480581     PISSN: 17401526     EISSN: 17401534     Source Type: Journal    
DOI: 10.1038/nrmicro3360     Document Type: Review

References (60)

1. Barouch, D. H. The quest for an HIV-1 vaccine-moving forward. N. Engl. J. Med. 369, 2073-2076 (2013).
2. Fauci, A. S. & Marston, H. D. Ending AIDS-is an HIV vaccine necessary? N. Engl. J. Med. 370, 495-498 (2014).
3. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
4. Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
5. Gray, G. E. et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect. Dis. 11, 507-515 (2011).
6. Hammer, S. M. et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369, 2083-2092 (2013).
7. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
8. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
9. Shiver, J. W. & Emini, E. A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
10. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
11. Casimiro, D. R. et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79, 15547-15555 (2005).
12. Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875-5885 (2006).
13. Benlahrech, A. et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl Acad. Sci. USA 106, 19940-19945 (2009).
14. + T cells. Nature Med. 15, 876-878 (2009).
15. McElrath, M. J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905 (2008).
16. O'Brien, K. L. et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nature Med. 15, 873-875 (2009).
17. Letvin, N. L. et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3, ra36 (2011).
18. Lopker, M. et al. Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J. Virol. 87, 5477-5492 (2013).
19. Barouch, D. H. et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29, 5203-5209 (2011).
20. Mast, T. C. et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28, 950-957 (2010).
21. Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654-4663 (2007).
22. Baden, L. R. et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 207, 240-247 (2013).
23. Barouch, D. H. et al. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001). J. Infect. Dis. 207, 248-256 (2013).
24. Creech, C. B. et al. Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults. Hum. vaccin. Immunother. 9, 2548-2557 (2013).
25. Keefer, M. C. et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS ONE 7, e41936 (2012).
26. Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263-8271 (2003).
27. Antrobus, R. D. et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol. Ther. 22, 668-674 (2013).
28. Barnes, E. et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4, ra111 (2012).
29. Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4, ra112 (2012).
30. O'Hara, G. A. et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J. Infect. Dis. 205, 772-781 (2012).
31. Li, H. et al. Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J. Virol. 86, 10862-10865 (2012).
32. Waddington, S. N. et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409 (2008).
33. Perreau, M. et al. The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes. J. Virol. 86, 6279-6285 (2012).
34. + T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J. Immunol. 190, 2720-2735 (2013).
35. Teigler, J. E., Iampietro, M. J. & Barouch, D. H. Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J. Virol. 86, 9590-9598 (2012).
36. Penaloza-MacMaster, P. et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J. Virol. 87, 1373-1384 (2013).
37. + T cells induced by different adenovirus vectors. J. Virol. 87, 1359-1372 (2013).
38. Liu, J. et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852 (2008).
39. Barouch, D. H. et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482, 89-93 (2012).
40. Barouch, D. H. et al. Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nature Med. 16, 319-323 (2010).
41. Fischer, W. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Med. 13, 100-106 (2007).
42. + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nature Med. 16, 324-328 (2010).
43. Barouch, D. H. et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539 (2013).
44. Baden, L. R. et al. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiu485 (2014).
45. Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527 (2011).
46. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100-104 (2013).
47. Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med. 15, 293-299 (2009).
48. + T cells is critical for superinfection by cytomegalovirus. Science 328, 102-106 (2010).
49. + T cell epitope recognition paradigms. Science 340, 1237874 (2013).
50. + T-cell development. Eur. J. Immunol. 39, 2083-2087 (2009).
51. + T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J. Intern. Med. 265, 67-77 (2009).
52. Picker, L. J. et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Invest. 116, 1514-1524 (2006).
53. Pitcher, C. J. et al. Development and homeostasis of T cell memory in rhesus macaque. J. Immunol. 168, 29-43 (2002).
54. Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004).
55. Grossman, Z., Meier-Schellersheim, M., Paul, W. E. & Picker, L. J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nature Med. 12, 289-295 (2006).
56. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
57. + T cell response by attenuated SIV infection. J. Exp. Med. 203, 2661-2672 (2006).
58. pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur. J. Immunol. 29, 2908-2915 (1999).
59. Picker, L. J., Hansen, S. G. & Lifson, J. D. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63, 95-111 (2012).
60. Fruh, K., Malouli, D., Oxford, K. L. & Barry, P. A. in Cytomegalovirus Vol. 2. (ed. Reddehase, M. J.) (Caister Academic Press, 2013).